Brief: Ryvu Therapeutics Got Full Approval To Conduct Phase I/II Study Of RVU120 In Patients With Relapsed/Refractory Metastatic Or Advanced Solid Tumors In Poland
28/05/2021 13:09
May 28 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* RYVU THERAPEUTICS GOT FULL APPROVAL TO CONDUCT PHASE I/II
STUDY
OF RVU120 (SEL120) IN PATIENTS WITH RELAPSED/REFRACTORY
METASTATIC OR ADVANCED SOLID TUMORS IN POLAND
Source text for Eikon: ID:nPn5B3XPya
Further company coverage: RVU.WA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project